ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

For this study, unfavorable intermediate risk prostate cancer patients will select whether they are to be treated with the standard of care (SOC) 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic body radiation therapy/radiosurgery (SBRT) directed to the prostate versus SBRT alone. The patient population will include those with National Comprehensive Cancer Network (NCCN)-defined unfavorable intermediate risk disease. All patients will be followed every 6 months for up to 5 years from the first patient treated and will undergo a routine 24-30 months post-SBRT pros

Trial Details

NCT ID
NCT06397703
Phase
PHASE2
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Leuprolide, Degarelix or Relugolix
  • Stereotactic body radiation therapy/radiosurgery (SBRT)
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Biopsy proven unfavorable intermediate risk prostate cancer, which includes patients with any one of the following variables: Gleason 4+3 disease; …
  • Patients must have tissue available for Decipher score testing. Results must be available before start of treatment.
  • Serum testosterone ≥ 150 ng/dL determined within 2 months prior to enrollment
  • At least 4 weeks must have elapsed from major surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →